Skip to main content
CBIO logo

Crescent Biopharma, Inc.

CBIONASDAQHealthcareBiotechnology

$12.76Today:- (-)1Y +2.74%

As of Oct 26, 2026 close

Market cap
$426.47M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$8.72$27.41
Volume (live)
-
Avg. volume (3M)
458.61K

Crescent Biopharma (CBIO) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Crescent Biopharma had return on equity of -160.8%, debt-to-equity of 0.01 (up from -3.27), a current ratio of 6.56 (up from 3.62) and return on assets of -69.2%. A current ratio of 6.56 means current assets exceed current liabilities.

Crescent Biopharma Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Valuation Ratios
P/S Ratio21.38-15196.902196.8664.95
P/B Ratio1.14----
Price/Tangible Book1.17----
Enterprise Value Ratios
EV/Revenue9.62-11091.801570.83-12.00
EV/EBITDA----0.22
EV/EBIT----0.22
EV/FCF----0.24
Profitability & Returns
Return on Equity (ROE)-160.75%--90.78%-75.05%-60.49%
Return on Assets (ROA)-69.15%--80.87%-64.87%-53.50%
Return on Invested Capital (ROIC)---1834.55%-1442.19%-1266.82%
Return on Capital Employed (ROCE)-74.70%-264.40%-96.49%-75.57%-59.60%
Leverage & Solvency Ratios
Debt/Equity0.01-3.270.000.000.00
Liquidity Ratios
Current Ratio6.563.626.415.717.68
Quick Ratio6.413.626.115.397.63
Efficiency Ratios
Asset Turnover0.08-0.000.000.01
Yield & Distribution Ratios
Earnings Yield-66.39%----
FCF Yield-31.25%----
Buyback Yield-1465.00%--20.58%-2.10%-12.54%
Total Return---20.58%-2.10%-12.54%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Crescent Biopharma Financial Ratios

What is Crescent Biopharma's return on equity?

Crescent Biopharma's return on equity (ROE) was -160.8% for fiscal 2025 (period ended Dec 31, 2025).

What is Crescent Biopharma's debt-to-equity ratio?

Crescent Biopharma's debt-to-equity ratio was 0.01 for fiscal 2025 (period ended Dec 31, 2025). It was -3.27 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition